PIK3CA and ductal breast carcinoma in situ: Data from the COSMIC database supports this idea, with PIK3CA mutation detected in 49% of hyperplasia, 29% of DCIS, and 24% in IDCs [6], suggesting the level of PIK3CA mutation decreases as disease progression ensues.